**1. Phylogeny**  
Mitogen‐activated protein kinase 11 (MAPK11), more widely known as p38 beta, SAPK2B, or p38‑2, belongs to the p38 MAPK subgroup within the larger CMGC group of serine/threonine kinases. Phylogenetically, this subgroup includes four closely related isoforms – namely, MAPK14 (p38 alpha), MAPK11 (p38 beta), MAPK12 (p38 gamma) and MAPK13 (p38 delta) – that share significant sequence conservation in their catalytic domains while displaying differences in regulatory regions and tissue expression patterns (alnafisah2023alteredkinasenetworks pages 50-55, dahm2025atypicalmapksin pages 1-3). The evolutionary origins of the p38 family can be traced back to a common ancestor among eukaryotes, with orthologs identified broadly in mammals and many other vertebrate lineages. This evolutionary conservation points to the fundamental role these kinases have in mediating cellular stress responses and inflammatory signaling across species (amakiri2021cellsignallinginterplay pages 7-11). In particular, the observed functional redundancy between MAPK11 and MAPK14 suggests that an ancient gene duplication event gave rise to these isoforms, after which they conserved the essential mechanism needed to orchestrate stress and cytokine responses. The conservation of specific motifs, such as the dual phosphorylation T-G-Y activation loop, further underscores the evolutionary pressure to maintain MAPK11’s catalytic function and regulatory interactions (alnafisah2023alteredkinasenetworks pages 50-55, deepak2016pathwayanalysisof pages 81-87).

**2. Reaction Catalyzed**  
MAPK11 functions as a serine/threonine kinase and catalyzes the transfer of a phosphate group from ATP to target substrates. The reaction follows the canonical ATP‐dependent phosphorylation mechanism typical of the MAPK family. More precisely, the chemical transformation can be represented as:  
  ATP + protein-(L-serine or L-threonine) → ADP + protein-(phospho-serine/threonine) + H⁺.  
This reaction involves the binding of ATP in the kinase’s active site, where, following appropriate alignment with the protein substrate, the γ-phosphate of ATP is transferred to the hydroxyl group of a serine or threonine residue. In doing so, MAPK11 modulates substrate activity and initiates signal propagation cascades in response to extracellular stimuli such as pro-inflammatory cytokines or stress signals (higgins2023sarscov2hijacksp38βmapk11 pages 21-23, invergo2022accuratehighcoverageassignment pages 21-24). The substrate proteins include both components of the downstream kinase cascades and non-kinase targets, which, upon phosphorylation, either change their enzymatic activity, binding capacity, or subcellular localization. This enzymatic process is fundamental to the modulation of immediate-early gene induction as well as to various regulatory networks that govern cell survival, apoptosis, and inflammatory responses (liu2021leveragingdiversedata pages 33-36, amakiri2021cellsignallinginterplay pages 48-52).

**3. Cofactor Requirements**  
MAPK11 exhibits the classical cofactor requirement characteristic of serine/threonine kinases. The enzyme depends predominantly on divalent metal ions, with Mg²⁺ being indispensable for its catalytic activity. Mg²⁺ ions bind to ATP and assist in the proper orientation of the phosphate groups within the active site, thereby stabilizing the transition state during the phosphoryl transfer reaction. Without Mg²⁺, ATP binding is inefficient and the phosphorylation reaction cannot proceed at a physiologically significant rate (higgins2023sarscov2hijacksp38βmapk11 pages 21-23, moret2020aresourcefor pages 39-43). In addition to Mg²⁺, while no other cofactors have been definitively shown to be essential for MAPK11’s catalytic activity, the kinase’s regulation is achieved via phosphorylation by upstream kinases and possibly through interactions with scaffold proteins that modify its substrate selectivity and subcellular distribution (liu2021leveragingdiversedata pages 69-74, maikrachline2020nuclearp38roles pages 4-6).

**4. Substrate Specificity**  
MAPK11 demonstrates broad and promiscuous substrate specificity typical of p38 MAP kinases, with estimates suggesting that it phosphorylates between 200 to 300 distinct target proteins. Several of these substrates are itself kinases, contributing to layered signaling cascades. For example, MAPK11 directly phosphorylates downstream kinases such as RPS6KA5 (MSK1) and RPS6KA4 (MSK2), which then further phosphorylate key transcription factors including CREB1, ATF1, and the NF‑κB isoform RELA (NFKB3) (alnafisah2023alteredkinasenetworks pages 50-55, amakiri2021cellsignallinginterplay pages 7-11). The activation of MSK kinases cascades into triggering transcription factors that can reshape immediate-early gene expression programs and induce chromatin remodeling by phosphorylating histone H3 and the nucleosomal protein HMGN1.

Moreover, MAPK11 phosphorylates other pivotal downstream targets such as MAPKAPK2 (MK2) and MAPKAPK3 (MK3); these kinases modulate gene expression on a post-transcriptional level by phosphorylating RNA binding proteins such as ZFP36 (tristetraprolin) and ELAVL1, and by regulating the activity of elongation factor EEF2K, which is essential for mRNA translation elongation (alnafisah2023alteredkinasenetworks pages 50-55, invergo2022accuratehighcoverageassignment pages 10-12). Additionally, kinases such as MKNK1 and MKNK2, which are activated by MAPK11, engage in the regulation of protein synthesis through the phosphorylation of the initiation factor EIF4E2, thereby affecting translational control at the onset of protein synthesis (liu2021leveragingdiversedata pages 33-36).

Beyond these kinase cascades, MAPK11 phosphorylates cytoplasmic proteins such as CFLAR, thereby modulating its stability via proteasome-mediated degradation and influencing the cell’s apoptotic threshold. It also regulates the ectodomain shedding of transmembrane proteins by phosphorylating ADAM17, which facilitates the release of TGF-alpha family ligands, ultimately leading to the activation of the EGFR signaling pathway and promoting cell proliferation (amakiri2021cellsignallinginterplay pages 48-52, roche2020p38βandcancer pages 8-10). In the nucleus, MAPK11 phosphorylates an extensive array of transcription factors—including ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, and TP53/p53—as well as transcription cofactors such as MEF2C and MEF2A. These phosphorylation events modulate gene expression by affecting chromatin structure, for instance through the enhancement of histone H3 Ser-10 phosphorylation, which increases the accessibility of promoters for inflammatory genes like IL6, IL8, and IL12B (cann2017identifyingtherapeuticagents pages 176-178, li2015unravelingtherole pages 87-91). Additional substrates include components of the inflammasome; under conditions of UV-B irradiation or ribosomal stress, MAPK11 phosphorylates NLRP1 downstream of MAP3K20/ZAK, thereby triggering inflammasome activation and pyroptosis (alnafisah2023alteredkinasenetworks pages 50-55, jha2025deeplearningcoupledproximity pages 22-24). Recent findings also indicate that MAPK11 phosphorylates the methyltransferase DOT1L on multiple serine and threonine residues, suggesting a role in the epigenetic regulation of gene expression by altering chromatin methylation states (karimbayli2024insightsintothe pages 15-17). Although the precise recognition motifs remain less clearly defined owing to the generally short consensus sequence (Ser/Thr-Pro) employed by MAPKs, the contextual contributions of substrate docking sites are critical—these include D domains and DEF motifs that facilitate high-affinity substrate interactions (alnafisah2023alteredkinasenetworks pages 50-55, invergo2022accuratehighcoverageassignment pages 21-24).

**5. Structure**  
MAPK11 possesses a canonical kinase structure typical of the MAPK family. Its structure is organized around a central catalytic domain that exhibits a bilobal arrangement. The N-terminal lobe is predominantly composed of β-sheets, whereas the C-terminal lobe is richer in α-helices. This bilobal architecture creates an inter-lobe cleft that functions as the ATP-binding pocket, a defining feature in serine/threonine kinases (moret2020aresourcefor pages 39-43, gogl2019disorderedproteinkinase pages 8-10). The kinase domain includes an activation loop that contains the conserved dual phosphorylation motif (T-G-Y) – a sequence critical for full enzymatic activation. In MAPK11, phosphorylation of both the threonine and tyrosine residues within this motif induces a conformational change from an inactive to an active state, facilitating substrate binding and catalytic turnover (higgins2023sarscov2hijacksp38βmapk11 pages 21-23, dahm2025atypicalmapksin pages 1-3).

Structural studies, although more extensively performed on the closely related p38α, have provided insights into MAPK11’s tertiary structure through homology modeling and limited high-resolution crystallographic data on related isoforms; these suggest that differences may exist in the precise topography of the ATP-binding site. In particular, subtle variations at the periphery of the catalytic cleft may account for differences in inhibitor sensitivity and substrate specificity between MAPK11 and its homologues (roche2020p38βandcancer pages 8-10, karimbayli2024insightsintothe pages 1-2). In addition to the catalytic domain, MAPK11 contains surface grooves and docking regions—commonly referred to as D-domains and DEF motifs—that are necessary for the recognition and effective binding of downstream substrates. These docking sites help in aligning substrates in the correct orientation relative to the active site, thereby fine-tuning the phosphorylation reaction (jha2025deeplearningcoupledproximity pages 24-26, maikrachline2020nuclearp38roles pages 4-6). Furthermore, disordered regions flanking the kinase domain might contribute to regulatory interactions and may influence subcellular localization, similar to what is observed in other MAPK family members (gogl2019disorderedproteinkinase pages 8-10).

**6. Regulation**  
The regulation of MAPK11 is intricately controlled by multiple layers of cellular signaling mechanisms. At the most fundamental level, activation of MAPK11 occurs through dual phosphorylation of its activation loop – specifically at the threonine and tyrosine residues within the T-G-Y motif (dahm2025atypicalmapksin pages 1-3, invergo2022accuratehighcoverageassignment pages 21-24). This phosphorylation is mediated primarily by the upstream MAP kinase kinases MKK3 and MKK6, which serve as key activators in response to extracellular signals such as pro-inflammatory cytokines and physical stresses (amakiri2021cellsignallinginterplay pages 48-52, li2015unravelingtherole pages 94-97). The resulting conformational change in MAPK11 transitions the enzyme from a relatively inactive to a fully active state, capable of efficient substrate phosphorylation.

Autophosphorylation can also play a role in fine-tuning MAPK11’s activity. Intrinsic autophosphorylation events, although not as well characterized as those in some other kinases, may further stabilize the active conformation or modulate basal kinase activity under certain cellular conditions (roche2020p38βandcancer pages 8-10, mullerdott2025fromactivityinference pages 48-52). Scaffold proteins and interacting partners further contribute to the regulation of MAPK11 by localizing both the kinase and its substrates to specific subcellular compartments, thus ensuring spatial and temporal coordination of the signaling cascade. Additionally, phosphatases play a critical role in deactivating MAPK11 by removing phosphate groups from the activation loop, thereby terminating the signal; these regulatory phosphatases help maintain the balance between kinase activation and inactivation during continuous cellular signaling (higgins2023sarscov2hijacksp38βmapk11 pages 21-23, maikrachline2020nuclearp38roles pages 4-6).

Cross-talk with other intracellular signaling pathways further modulates MAPK11 activity. For instance, feedback loops that involve downstream kinases and transcription factors may modulate upstream signaling events through both positive and negative regulatory circuits. In certain contexts, these pathways converge to influence not only the phosphorylation status of MAPK11 but also its subcellular localization and interaction with specific substrates (liu2021leveragingdiversedata pages 74-78, jha2025deeplearningcoupledproximity pages 22-24). Moreover, non-canonical mechanisms – such as phosphorylation by atypical kinases under certain stress conditions – have been reported to also influence MAPK11 activity, albeit in a less well-defined manner (dahm2025atypicalmapksin pages 1-3, katopodis2021p38βmapk11 pages 1-2).

**7. Function**  
MAPK11 plays a multifaceted role in the cellular response to stress and inflammatory stimuli. Acting as a central component of the MAP kinase signal transduction pathway, MAPK11 translates extracellular cues—such as exposure to pro-inflammatory cytokines and various physical stresses—into intracellular responses that affect gene expression, protein turnover, and cell fate decisions (alnafisah2023alteredkinasenetworks pages 50-55, deepak2016pathwayanalysisof pages 81-87).

In the cytoplasm, one of the critical functions of MAPK11 is the regulation of protein turnover. For example, MAPK11 phosphorylates CFLAR, an inhibitor of TNF-induced apoptosis, thereby marking it for proteasomal degradation. This regulation of apoptosis ensures that cells are able to appropriately undergo programmed cell death when stressed, or conversely, avoid premature apoptosis under less severe conditions (cann2017identifyingtherapeuticagents pages 173-176, liu2021leveragingdiversedata pages 142-144). Additionally, MAPK11 modulates ectodomain shedding by phosphorylating the membrane-associated metalloprotease ADAM17. The activation of ADAM17 leads to the shedding of TGF-alpha family ligands, which in turn triggers EGFR signaling pathways that stimulate cell proliferation and survival—a process that is particularly relevant in contexts of inflammation and cancer development (amakiri2021cellsignallinginterplay pages 48-52, roche2020p38βandcancer pages 8-10).

Moreover, MAPK11 has a pivotal role in receptor signaling through its regulation of FGFR1. Phosphorylation events mediated by MAPK11 facilitate the translocation of FGFR1 from the extracellular membrane to the cytosol and nucleus, where it participates in processes such as rRNA synthesis and cell growth. This kinase-mediated receptor trafficking thereby influences critical cellular functions, including those related to proliferation and metabolic regulation (liu2021leveragingdiversedata pages 142-144, moret2020aresourcefor pages 23-26).

Within the nucleus, MAPK11 exerts extensive control over gene expression. It phosphorylates multiple transcription factors—including ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, and TP53/p53—as well as transcription cofactors like MEF2C and MEF2A. These phosphorylation events alter the transcription factor activity and promote the rapid induction of immediate-early genes, particularly in response to cellular stress. A key molecular mechanism involves the phosphorylation of histone H3 at Ser-10 near promoters of inflammatory genes such as IL6, IL8, and IL12B, which enhances the recruitment of NF‑κB and thereby stimulates the transcription of cytokine genes during inflammatory responses (cann2017identifyingtherapeuticagents pages 176-178, maikrachline2020nuclearp38roles pages 4-6).

Furthermore, MAPK11 is implicated in innate immune signaling through its ability to phosphorylate components of the inflammasome. Under conditions of UV-B irradiation or ribosomal stress leading to collisions, MAPK11 phosphorylates NLRP1 downstream of MAP3K20/ZAK, resulting in the activation of the NLRP1 inflammasome and subsequent pyroptotic cell death. This mechanism serves as a protective measure against cellular damage and helps in regulating inflammation (alnafisah2023alteredkinasenetworks pages 50-55, jha2025deeplearningcoupledproximity pages 22-24).

Beyond these signaling roles, MAPK11 also appears to participate in the control of epigenetic modifications. For instance, phosphorylation of the methyltransferase DOT1L at several serine and threonine residues has been linked to alterations in chromatin structure, suggesting that MAPK11 may influence gene expression by modulating the epigenetic landscape during cellular stress and inflammatory responses (karimbayli2024insightsintothe pages 15-17, alnafisah2023alteredkinasenetworks pages 50-55). Collectively, these functions place MAPK11 as a central integrator of diverse signaling pathways that control cell proliferation, apoptosis, immune responses, and chromatin remodeling under varying physiological and pathological conditions.

**8. Other Comments**  
An important challenge in studying MAPK11 is its functional redundancy with MAPK14 (p38 alpha). While both isoforms share many substrates and regulatory mechanisms, subtle differences in substrate affinity, tissue expression, and inhibitor sensitivity suggest that MAPK11 has unique contributions that remain to be fully elucidated (alnafisah2023alteredkinasenetworks pages 50-55, katopodis2021p38βmapk11 pages 1-2). The broad substrate repertoire of MAPK11—which encompasses key regulators of transcription, mRNA translation, protein turnover, and even epigenetic modifications—underlines its vital role as an integrative hub in the cellular stress response network (liu2021leveragingdiversedata pages 69-74, ivan2021posttranslationalproteinmodifications pages 127-130).

MAPK11’s involvement in processes such as ectodomain shedding, inflammasome activation, and receptor translocation has spurred interest in characterizing its potential as a therapeutic target in inflammatory disorders and cancer. Several studies have demonstrated that targeting components of the p38 MAPK pathway can modulate tumor growth and inflammatory responses, although selective inhibitors for MAPK11 remain under active development (madkour2021currentstatusand pages 2-2, roche2020p38βandcancer pages 8-10). In addition, chemical genetic approaches and deep-learning coupled proximity proteomic techniques are being employed to improve our understanding of MAPK11’s network interactions and substrate specificity, paving the way for the development of more selective and efficacious small molecule inhibitors (jha2025deeplearningcoupledproximity pages 12-14, liu2021leveragingdiversedata pages 74-78).

The challenges in isoform-specific detection, partly due to the high sequence and structural similarity among p38 MAPK family members, underscore the importance of developing more refined biochemical reagents and high-throughput assays. Accurate discrimination between MAPK11 and MAPK14 is particularly important given their overlapping yet distinct roles in cellular signaling pathways, and such discrimination will be critical for discerning the precise biological functions of each isoform (gogl2019disorderedproteinkinase pages 8-10, moret2020aresourcefor pages 26-29). Lastly, while the detailed three-dimensional structural features of MAPK11 have not been as widely characterized as those of p38α, current studies indicate that subtle differences in the ATP-binding pocket and substrate docking regions could serve as the basis for isoform-selective inhibitor design, which represents a significant opportunity in therapeutic development (roche2020p38βandcancer pages 8-10, karimbayli2024insightsintothe pages 15-17).

**9. References**  
1. alnafisah2023alteredkinasenetworks pages 50-55  
2. amakiri2021cellsignallinginterplay pages 48-52  
3. amakiri2021cellsignallinginterplay pages 7-11  
4. blessing2015thee3ligase pages 17-21  
5. cann2017identifyingtherapeuticagents pages 173-176  
6. cann2017identifyingtherapeuticagents pages 176-178  
7. dahm2025atypicalmapksin pages 1-3  
8. deepak2016pathwayanalysisof pages 81-87  
9. garciahernandez2021thep38mapk pages 22-23  
10. gogl2019disorderedproteinkinase pages 8-10  
11. higgins2023sarscov2hijacksp38βmapk11 pages 21-23  
12. invergo2022accuratehighcoverageassignment pages 1-3  
13. invergo2022accuratehighcoverageassignment pages 10-12  
14. invergo2022accuratehighcoverageassignment pages 21-24  
15. ivan2021posttranslationalproteinmodifications pages 127-130  
16. jha2025deeplearningcoupledproximity pages 12-14  
17. jha2025deeplearningcoupledproximity pages 22-24  
18. jha2025deeplearningcoupledproximity pages 24-26  
19. karimbayli2024insightsintothe pages 1-2  
20. karimbayli2024insightsintothe pages 15-17  
21. katopodis2021p38βmapk11 pages 1-2  
22. li2015unravelingtherole pages 87-91  
23. li2015unravelingtherole pages 94-97  
24. liu2021leveragingdiversedata pages 142-144  
25. liu2021leveragingdiversedata pages 33-36  
26. liu2021leveragingdiversedata pages 69-74  
27. liu2021leveragingdiversedata pages 74-78  
28. madkour2021currentstatusand pages 2-2  
29. maikrachline2020nuclearp38roles pages 4-6  
30. moret2020aresourcefor pages 1-4  
31. moret2020aresourcefor pages 13-17  
32. moret2020aresourcefor pages 23-26  
33. moret2020aresourcefor pages 26-29  
34. moret2020aresourcefor pages 39-43  
35. moret2020aresourcefor pages 4-7  
36. moret2020aresourcefor pages 51-54  
37. mullerdott2025fromactivityinference pages 48-52  
38. nedunuri2016insilicopathway pages 7-11  
39. roche2020p38βandcancer pages 1-3  
40. roche2020p38βandcancer pages 8-10  
41. roche2020p38βandcancer pages 13-14

References

1. (alnafisah2023alteredkinasenetworks pages 50-55): R Alnafisah. Altered kinase networks in major depressive disorder. Unknown journal, 2023.
2. (amakiri2021cellsignallinginterplay pages 48-52): A Amakiri. Cell signalling interplay between phosphorylation and other post-translational modifications on a global scale. Unknown journal, 2021.
3. (amakiri2021cellsignallinginterplay pages 7-11): A Amakiri. Cell signalling interplay between phosphorylation and other post-translational modifications on a global scale. Unknown journal, 2021.
4. (blessing2015thee3ligase pages 17-21): N Blessing. The e3 ligase chip mediates ubiquitination and degradation of mixed lineage kinase 3 and mixed lineage kinase 4 beta. Unknown journal, 2015.
5. (cann2017identifyingtherapeuticagents pages 173-176): M Cann. Identifying therapeutic agents for the treatment of diffuse large b-cell lymphoma. Unknown journal, 2017.
6. (cann2017identifyingtherapeuticagents pages 176-178): M Cann. Identifying therapeutic agents for the treatment of diffuse large b-cell lymphoma. Unknown journal, 2017.
7. (dahm2025atypicalmapksin pages 1-3): Katrin Dahm, Parthiban Vijayarangakannan, Hans‐Peter Wollscheid, Hansjörg Schild, and Krishnaraj Rajalingam. Atypical mapks in cancer. The FEBS Journal, Sep 2025. URL: https://doi.org/10.1111/febs.17283, doi:10.1111/febs.17283. This article has 1 citations.
8. (deepak2016pathwayanalysisof pages 81-87): N. Deepak, Yesu babu Adimulam, and R. Kiran Kumar. Pathway analysis of highly conserved mitogen activated protein kinases (mapks). SpringerBriefs in Applied Sciences and Technology, pages 71-82, Jan 2016. URL: https://doi.org/10.1007/978-981-10-0391-2\_7, doi:10.1007/978-981-10-0391-2\_7. This article has 2 citations and is from a peer-reviewed journal.
9. (garciahernandez2021thep38mapk pages 22-23): Laura García-Hernández, María Belén García-Ortega, Gloria Ruiz-Alcalá, Esmeralda Carrillo, Juan Antonio Marchal, and María Ángel García. The p38 mapk components and modulators as biomarkers and molecular targets in cancer. International Journal of Molecular Sciences, 23:370, Dec 2021. URL: https://doi.org/10.3390/ijms23010370, doi:10.3390/ijms23010370. This article has 87 citations and is from a peer-reviewed journal.
10. (gogl2019disorderedproteinkinase pages 8-10): Gergő Gógl, Alexandr P. Kornev, Attila Reményi, and Susan S. Taylor. Disordered protein kinase regions in regulation of kinase domain cores. Trends in Biochemical Sciences, 44:300-311, Apr 2019. URL: https://doi.org/10.1016/j.tibs.2018.12.002, doi:10.1016/j.tibs.2018.12.002. This article has 74 citations and is from a domain leading peer-reviewed journal.
11. (higgins2023sarscov2hijacksp38βmapk11 pages 21-23): Christina A. Higgins, Benjamin E. Nilsson-Payant, Boris Bonaventure, Andrew P. Kurland, Chengjin Ye, Tomer M. Yaron, Jared L. Johnson, Prithy Adhikary, Ilona Golynker, Maryline Panis, Oded Danziger, Brad R. Rosenberg, Lewis C. Cantley, Luis Martínez-Sobrido, Benjamin tenOever, and Jeffrey R. Johnson. Sars-cov-2 hijacks p38β/mapk11 to promote virus replication. mBio, Jun 2023. URL: https://doi.org/10.1128/mbio.01007-23, doi:10.1128/mbio.01007-23. This article has 9 citations and is from a domain leading peer-reviewed journal.
12. (invergo2022accuratehighcoverageassignment pages 1-3): BM Invergo. Accurate, high-coverage assignment of in vivo protein kinases to phosphosites from in vitro phosphoproteomic specificity data. PLoS Computational Biology, Sep 2022. URL: https://doi.org/10.1101/2021.08.31.458376, doi:10.1101/2021.08.31.458376. This article has 1 citations and is from a highest quality peer-reviewed journal.
13. (invergo2022accuratehighcoverageassignment pages 10-12): BM Invergo. Accurate, high-coverage assignment of in vivo protein kinases to phosphosites from in vitro phosphoproteomic specificity data. PLoS Computational Biology, Sep 2022. URL: https://doi.org/10.1101/2021.08.31.458376, doi:10.1101/2021.08.31.458376. This article has 1 citations and is from a highest quality peer-reviewed journal.
14. (invergo2022accuratehighcoverageassignment pages 21-24): BM Invergo. Accurate, high-coverage assignment of in vivo protein kinases to phosphosites from in vitro phosphoproteomic specificity data. PLoS Computational Biology, Sep 2022. URL: https://doi.org/10.1101/2021.08.31.458376, doi:10.1101/2021.08.31.458376. This article has 1 citations and is from a highest quality peer-reviewed journal.
15. (ivan2021posttranslationalproteinmodifications pages 127-130): Silbern Ivan. Post-translational protein modifications involved in exo- and endocytosis of synaptic vesicles. 2021. URL: https://doi.org/10.53846/goediss-8895, doi:10.53846/goediss-8895.
16. (jha2025deeplearningcoupledproximity pages 12-14): Kanchan Jha, Daichi Shonai, Aditya Parekh, Akiyoshi Uezu, Tomoyuki Fujiyama, Hikari Yamamoto, Pooja Parameswaran, Masashi Yanagisawa, Rohit Singh, and Scott H. Soderling. Deep learning-coupled proximity proteomics to deconvolve kinase signaling in vivo. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.27.650849, doi:10.1101/2025.04.27.650849. This article has 0 citations.
17. (jha2025deeplearningcoupledproximity pages 22-24): Kanchan Jha, Daichi Shonai, Aditya Parekh, Akiyoshi Uezu, Tomoyuki Fujiyama, Hikari Yamamoto, Pooja Parameswaran, Masashi Yanagisawa, Rohit Singh, and Scott H. Soderling. Deep learning-coupled proximity proteomics to deconvolve kinase signaling in vivo. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.27.650849, doi:10.1101/2025.04.27.650849. This article has 0 citations.
18. (jha2025deeplearningcoupledproximity pages 24-26): Kanchan Jha, Daichi Shonai, Aditya Parekh, Akiyoshi Uezu, Tomoyuki Fujiyama, Hikari Yamamoto, Pooja Parameswaran, Masashi Yanagisawa, Rohit Singh, and Scott H. Soderling. Deep learning-coupled proximity proteomics to deconvolve kinase signaling in vivo. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.27.650849, doi:10.1101/2025.04.27.650849. This article has 0 citations.
19. (karimbayli2024insightsintothe pages 1-2): Javad Karimbayli, Ilenia Pellarin, Barbara Belletti, and Gustavo Baldassarre. Insights into the structural and functional activities of forgotten kinases: pctaires cdks. Molecular Cancer, Jun 2024. URL: https://doi.org/10.1186/s12943-024-02043-6, doi:10.1186/s12943-024-02043-6. This article has 4 citations and is from a highest quality peer-reviewed journal.
20. (karimbayli2024insightsintothe pages 15-17): Javad Karimbayli, Ilenia Pellarin, Barbara Belletti, and Gustavo Baldassarre. Insights into the structural and functional activities of forgotten kinases: pctaires cdks. Molecular Cancer, Jun 2024. URL: https://doi.org/10.1186/s12943-024-02043-6, doi:10.1186/s12943-024-02043-6. This article has 4 citations and is from a highest quality peer-reviewed journal.
21. (katopodis2021p38βmapk11 pages 1-2): Periklis Katopodis, Rachel Kerslake, Athanasios Zikopoulos, Nefeli Beri, and Vladimir Anikin. P38β - mapk11 and its role in female cancers. Journal of Ovarian Research, Jun 2021. URL: https://doi.org/10.1186/s13048-021-00834-9, doi:10.1186/s13048-021-00834-9. This article has 24 citations and is from a peer-reviewed journal.
22. (li2015unravelingtherole pages 87-91): Lei Li. Unraveling the role of gp78/amfr : an e3 ubiquitin ligase and cell surface receptor, in cancer progression. Unknown journal, 2015. URL: https://doi.org/10.14288/1.0167674, doi:10.14288/1.0167674. This article has 0 citations.
23. (li2015unravelingtherole pages 94-97): Lei Li. Unraveling the role of gp78/amfr : an e3 ubiquitin ligase and cell surface receptor, in cancer progression. Unknown journal, 2015. URL: https://doi.org/10.14288/1.0167674, doi:10.14288/1.0167674. This article has 0 citations.
24. (liu2021leveragingdiversedata pages 142-144): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
25. (liu2021leveragingdiversedata pages 33-36): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
26. (liu2021leveragingdiversedata pages 69-74): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
27. (liu2021leveragingdiversedata pages 74-78): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
28. (madkour2021currentstatusand pages 2-2): Moustafa M. Madkour, Hanan S. Anbar, and Mohammed I. El-Gamal. Current status and future prospects of p38α/mapk14 kinase and its inhibitors. European Journal of Medicinal Chemistry, 213:113216, Mar 2021. URL: https://doi.org/10.1016/j.ejmech.2021.113216, doi:10.1016/j.ejmech.2021.113216. This article has 90 citations and is from a domain leading peer-reviewed journal.
29. (maikrachline2020nuclearp38roles pages 4-6): Galia Maik-Rachline, Lucia Lifshits, and Rony Seger. Nuclear p38: roles in physiological and pathological processes and regulation of nuclear translocation. International Journal of Molecular Sciences, 21:6102, Aug 2020. URL: https://doi.org/10.3390/ijms21176102, doi:10.3390/ijms21176102. This article has 65 citations and is from a peer-reviewed journal.
30. (moret2020aresourcefor pages 1-4): Nienke Moret, Changchang Liu, Benjamin M. Gyori, John A. Bachman, Albert Steppi, Clemens Hug, Rahil Taujale, Liang-Chin Huang, Matthew E. Berginski, Shawn M. Gomez, Natarajan Kannan, and Peter K. Sorger. A resource for exploring the understudied human kinome for research and therapeutic opportunities. BioRxiv, Apr 2020. URL: https://doi.org/10.1101/2020.04.02.022277, doi:10.1101/2020.04.02.022277. This article has 28 citations.
31. (moret2020aresourcefor pages 13-17): Nienke Moret, Changchang Liu, Benjamin M. Gyori, John A. Bachman, Albert Steppi, Clemens Hug, Rahil Taujale, Liang-Chin Huang, Matthew E. Berginski, Shawn M. Gomez, Natarajan Kannan, and Peter K. Sorger. A resource for exploring the understudied human kinome for research and therapeutic opportunities. BioRxiv, Apr 2020. URL: https://doi.org/10.1101/2020.04.02.022277, doi:10.1101/2020.04.02.022277. This article has 28 citations.
32. (moret2020aresourcefor pages 23-26): Nienke Moret, Changchang Liu, Benjamin M. Gyori, John A. Bachman, Albert Steppi, Clemens Hug, Rahil Taujale, Liang-Chin Huang, Matthew E. Berginski, Shawn M. Gomez, Natarajan Kannan, and Peter K. Sorger. A resource for exploring the understudied human kinome for research and therapeutic opportunities. BioRxiv, Apr 2020. URL: https://doi.org/10.1101/2020.04.02.022277, doi:10.1101/2020.04.02.022277. This article has 28 citations.
33. (moret2020aresourcefor pages 26-29): Nienke Moret, Changchang Liu, Benjamin M. Gyori, John A. Bachman, Albert Steppi, Clemens Hug, Rahil Taujale, Liang-Chin Huang, Matthew E. Berginski, Shawn M. Gomez, Natarajan Kannan, and Peter K. Sorger. A resource for exploring the understudied human kinome for research and therapeutic opportunities. BioRxiv, Apr 2020. URL: https://doi.org/10.1101/2020.04.02.022277, doi:10.1101/2020.04.02.022277. This article has 28 citations.
34. (moret2020aresourcefor pages 39-43): Nienke Moret, Changchang Liu, Benjamin M. Gyori, John A. Bachman, Albert Steppi, Clemens Hug, Rahil Taujale, Liang-Chin Huang, Matthew E. Berginski, Shawn M. Gomez, Natarajan Kannan, and Peter K. Sorger. A resource for exploring the understudied human kinome for research and therapeutic opportunities. BioRxiv, Apr 2020. URL: https://doi.org/10.1101/2020.04.02.022277, doi:10.1101/2020.04.02.022277. This article has 28 citations.
35. (moret2020aresourcefor pages 4-7): Nienke Moret, Changchang Liu, Benjamin M. Gyori, John A. Bachman, Albert Steppi, Clemens Hug, Rahil Taujale, Liang-Chin Huang, Matthew E. Berginski, Shawn M. Gomez, Natarajan Kannan, and Peter K. Sorger. A resource for exploring the understudied human kinome for research and therapeutic opportunities. BioRxiv, Apr 2020. URL: https://doi.org/10.1101/2020.04.02.022277, doi:10.1101/2020.04.02.022277. This article has 28 citations.
36. (moret2020aresourcefor pages 51-54): Nienke Moret, Changchang Liu, Benjamin M. Gyori, John A. Bachman, Albert Steppi, Clemens Hug, Rahil Taujale, Liang-Chin Huang, Matthew E. Berginski, Shawn M. Gomez, Natarajan Kannan, and Peter K. Sorger. A resource for exploring the understudied human kinome for research and therapeutic opportunities. BioRxiv, Apr 2020. URL: https://doi.org/10.1101/2020.04.02.022277, doi:10.1101/2020.04.02.022277. This article has 28 citations.
37. (mullerdott2025fromactivityinference pages 48-52): S Müller-Dott. From activity inference to multi-omics network contextualization: deciphering cellular signaling and disease mechanisms. Unknown journal, 2025.
38. (nedunuri2016insilicopathway pages 7-11): Deepak Nedunuri, Yesu babu Adimulam, and Kiran Kumar Reddi. In silico pathway analysis of mapks and computational investigation of bipyrazole analogues as novel p38alpha mapk inhibitors. Int. J. Bioinform. Res. Appl., 12:1-18, Mar 2016. URL: https://doi.org/10.1504/ijbra.2016.075395, doi:10.1504/ijbra.2016.075395. This article has 3 citations.
39. (roche2020p38βandcancer pages 1-3): Olga Roche, Diego M. Fernández-Aroca, Elena Arconada-Luque, Natalia García-Flores, Liliana F. Mellor, María José Ruiz-Hidalgo, and Ricardo Sánchez-Prieto. P38β and cancer: the beginning of the road. International Journal of Molecular Sciences, 21:7524, Oct 2020. URL: https://doi.org/10.3390/ijms21207524, doi:10.3390/ijms21207524. This article has 27 citations and is from a peer-reviewed journal.
40. (roche2020p38βandcancer pages 13-14): Olga Roche, Diego M. Fernández-Aroca, Elena Arconada-Luque, Natalia García-Flores, Liliana F. Mellor, María José Ruiz-Hidalgo, and Ricardo Sánchez-Prieto. P38β and cancer: the beginning of the road. International Journal of Molecular Sciences, 21:7524, Oct 2020. URL: https://doi.org/10.3390/ijms21207524, doi:10.3390/ijms21207524. This article has 27 citations and is from a peer-reviewed journal.
41. (roche2020p38βandcancer pages 8-10): Olga Roche, Diego M. Fernández-Aroca, Elena Arconada-Luque, Natalia García-Flores, Liliana F. Mellor, María José Ruiz-Hidalgo, and Ricardo Sánchez-Prieto. P38β and cancer: the beginning of the road. International Journal of Molecular Sciences, 21:7524, Oct 2020. URL: https://doi.org/10.3390/ijms21207524, doi:10.3390/ijms21207524. This article has 27 citations and is from a peer-reviewed journal.